SciELO - Scientific Electronic Library Online

 
vol.50 issue5Evaluation of carbapenem-resistant Enterobacteriaceae in a tertiary-level reference hospital in Rio Grande do Sul, BrazilSpatial risk of tuberculosis mortality and social vulnerability in Northeast Brazil author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

Share


Revista da Sociedade Brasileira de Medicina Tropical

Print version ISSN 0037-8682On-line version ISSN 1678-9849

Rev. Soc. Bras. Med. Trop. vol.50 no.5 Uberaba Sept./Oct. 2017

https://doi.org/10.1590/0037-8682-0025-2017 

Short Communication

Ex vivo T-lymphocyte chemokine receptor phenotypes in patients with chronic Chagas disease

Matheus Barbosa de Miranda1 

Adriene Siqueira de Melo2 

Mariana Silva Almeida1 

Silvia Martins Marinho3  4 

Wilson Oliveira Junior3 

Yara de Miranda Gomes1  4 

1Centro de Pesquisas Aggeu Magalhães, Fundação Oswaldo Cruz, Recife, PE, Brasil.

2Faculdade Pernambucana da Saúde, Recife, PE, Brasil.

3Ambulatório de Doença de Chagas e Insuficiência Cardíaca, Pronto Socorro Cardiológico de Pernambuco, Universidade de Pernambuco, Recife, PE, Brasil.

4Programa Integrado de Doença de Chagas, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, RJ, Brasil.


Abstract

INTRODUCTION:

Elucidating the molecules involved in the inflammatory process of chronic Chagas disease may allow identification of treatment targets.

METHODS:

The ex vivo phenotypic expression of chemokine receptors CCR1, CCR3, CCR4, CCR5, CXCR2, CXCR3, CXCR4, and CXCR5 on the CD4+ and CD8+ T-cells of patients with chronic Chagas cardiomyopathy of varying severity was evaluated using flow cytometry.

RESULTS:

Differential expression of CD4+CCR3+ and CD8+CCR4+ T-cells was observed in patients with mild cardiac involvement compared, respectively, with patients with severe cardiac and asymptomatic forms of Chagas disease.

CONCLUSIONS:

These receptors are possibly involved in the pathogenesis of chronic Chagas cardiomyopathy.

Keywords: Chronic Chagas disease; Cardiomyopathy; Chemokine receptors

Chagas disease, caused by the hemoflagellate protozoan Trypanosoma cruzi, presents with systemic features and follows a chronic evolution; it is a serious public health problem throughout Latin America1. The chronic phase of this disease comprises three main clinical forms: asymptomatic or indeterminate, cardiac, and digestive forms2. The cardiac form is associated with high morbidity and mortality, occurring mostly in symptomatic patients in the chronic phase of the disease. One of the main immunologic features of intracellular protozoan infections such as T. cruzi is polarization to a TH1 response. The TH1 response profile is characterized by a repertoire of proinflammatory cytokines, mainly tumor necrosis factor-α and interferon-γ, that play a role in parasite elimination and host survival3. However, if the inflammatory environment is modulated immunologically by the expression of anti-inflammatory cytokines such as interleukin-10, this may trigger a balanced response with consequent attenuation of inflammation4. Therefore, modulatory mechanisms are essential to prevent exacerbated inflammatory responses against the parasite, with consequent tissue injury. Evaluation of the inflammatory milieu in patients with chronic Chagas disease, by quantifying chemokine production and the expression chemokine receptors, could further our understanding of the mechanisms causing heart damage and they could help to explain the absence of clinical alterations among individuals with the indeterminate form of the disease.

Patients with chronic Chagas disease attending the Ambulatório de Doença de Chagas e Insuficiência Cardíaca do Pronto Socorro Cardiológico de Pernambuco (PROCAPE), Universidade de Pernambuco, Brazil, were selected. Patients were included according to following criteria: 1) positive serology for Chagas disease on enzyme-linked immunosorbent assay and immunofluorescence reaction (RIFI); 2) results of clinical tests and complementary examinations (physical examination, electrocardiography, chest radiography, Doppler echocardiography, and esophagography) were available to allow characterization of cardiac stages A, B (B1 and B2), C and D, according to the I Latin American Guidelines for the diagnosis and treatment of Chagas cardiomyopathy5; 3) absence of gastrointestinal symptoms and comorbidities (hypertension, diabetes, thyroid disease, and inflammatory and/or infectious diseases); and 4) absence of previous etiological treatment with benznidazole.

In total, 33 individuals (13 men and 20 women) were included in the study. The group of patients classified as having the indeterminate form of the disease (n = 12, aged ~56 years) comprised those with stage A cardiac involvement, i.e. without current or previous symptoms of heart failure and whose clinical tests were normal. Patients were classified as having a mild cardiac form of the disease (n = 10, aged ~68 years) if they were in stage B1, i.e. had electrocardiographic abnormalities (conduction disorders or arrhythmias) but had normal global ventricular function. Patients were classified as having a severe cardiac form of the disease (n = 11, age ~58 years) if they were in stage C, i.e. a previous or current clinical diagnosis of heart failure according to the Framingham criteria (simultaneous presence of two major criteria or one major criterion and two minor criteria)6 and evidence of ventricular dysfunction (systolic heart failure with a left ventricular ejection fraction <50%, as determined by Doppler echocardiography).

After collecting 10mL samples of blood in Becton Dickinson Vacutainers® containing sodium heparin, 100µL were used directly in the execution of the phenotypic expression protocol. Samples were immunostained by incubation for 30 min with fluorescein isothiocyanate-conjugated anti-CD8 (clone: 3B5, Caltag, Burlingame, CA, USA ); peridinin-chlorophyll protein complex-conjugated anti-CD4 (clone: S3.5, Invitrogen™, Carlsbad, CA, USA); Alexa Fluor-conjugated anti-CCR1 (clone: 5354), anti-CCR3 (clone: SF8), and anti-CXCR5 (clone: PF8B2; Becton Dickinson, Franklin Lakes, NJ, USA); and phycoerythrin-conjugated anti-CCR4 (clone: 161), anti-CCR5 (clone: 2D7/CCR5), anti-CXCR2 (clone: 6C6), anti-CXCR3 (clone: 1C6/CXCR3), and anti-CXCR4 (clone: 1D9; Becton Dickinson, Franklin Lakes, NJ, USA). After incubation, erythrocytes were lysed (FACS Lysing Solution; Becton Dickinson Bioscience), followed by washing in phosphate buffered saline containing 0.5% bovine serum albumin and 0.1% sodium azide (Sigma-Aldrich) and centrifugation (300 × g for 5 min).

Samples were processed using a BD FACSCalibur™ flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA), available on the Core Technology Platforms (NPT1) of Centro de Pesquisas Aggeu Magalhães/Fundação Oswaldo Cruz (CPqAM/FIOCRUZ). Sample acquisition and analysis were performed using BD Cell Quest™ Pro software. For each analysis, 20,000 events were acquired, gated on cluster of differentiation 4 (CD4+) and cluster of differentiation 8+ (CD8+) T-cell subpopulations expressing the chemokine receptors. The analysis was conducted by obtaining two-dimensional graphics of fluorescent punctual distributions.

The graphics were developed and the statistical tests performed using GraphPad Prism 6.0 software. Bartlett’s test for homogeneity of variance was first applied. To compare the median values of the phenotypic expression of chemokine receptors on the surface of T-cells among the groups of patients, the Kruskal-Wallis test was applied, followed by the multiple-comparison Dunn’s test when differences between medians were demonstrated. Statistical significance was set at 5% (α = 0.05).

The group of patients with mild cardiac disease had higher levels of CD4+ T-cells expressing the CCR3 receptor than did the group with severe cardiac disease (p = 0.03; Figure 1). In a study investigating associations between Chagas disease morbidity and the expression of cytokines and cytokine receptors, Gomes et al.7 described the CCR3 receptor as being a marker of the TH2 response; the expression of CCR3 was highest when the level of myocardial inflammation was low, as higher levels of CD4+ T-cell expression of CCR3 were observed in individuals with the mild cardiac form of Chagas disease than in those with severe cardiac involvement. Thus, in the present study, this receptor may be involved in the recruitment of and possibly in the mechanisms underlying the activation of CD4+ T-cells in individuals with the mild cardiac form of the disease, in a mechanism to compensate the progressive myocardial inflamation. The lower levels of CCR3 observed in patients with the severe cardiac form of Chagas disease might be due to the complete loss of immunoregulation, as this receptor is more closely associated with the TH2 response. In the present study, the expression of other chemokine receptors on the surface of CD4+ T-cells did not vary significantly between the different groups (Figure 1).

FIGURE 1 Ex vivo phenotype expression of chemokine receptors on the surface of CD4+ T-cells of patients with chronic Chagas disease. A: %CD4 CXCR2. B: %CD4 CXCR3. C: %CD4 CXCR4. D: %CD4 CXCR5. E: %CD4 CCR1. F: %CD4 CCR3. G: %CD4 CCR4. H: %CD4 CCR5. IND: indeterminate form (n = 12); CARD1: mild cardiac form (n = 10); CARD2: severe cardiac form (n = 11). CD4: cluster of differentiation 4; CXCR2, CXCR3, CXCR4, CXCR5, CCR1, CCR3, CCR4, CCR5: chemokine receptors. Median values are indicated by the horizontal lines. The Kruskal-Wallis test was performed, followed by Dunn’s test. Significant differences are indicated by arrows and exact p-values. 

The mild cardiac disease group had higher levels of CD8+ T-cells expressing the CCR4 receptor than did the indeterminate group (p = 0.02; Figure 2). Induction of cellular immunity and immune responses, mediated by CD8+ T-cells, is essential for the control of T. cruzi proliferation, as shown in murine models and in human infections8. The concomitant finding of the presence of Chagas disease and high numbers of CD8+ T-cells in experimental models has led some researchers to suggest that CD8+ T-cells cause the observed tissue damage9. Although CCR4 is a predominant receptor on TH2 cells, the fact that it has been observed to have greater expression in CD8+ T-cells suggests that CD8+ T-cells might use CCR4 for migrating to sites of inflammation. Hence, it is necessary to evaluate the production of cytokines as well as the production of perforins and granzymes in this particular subpopulation, to determine their possible role in the establishment of the disease their role is likely to be proinflammatory. Additionally Figure 2, demonstrates an apparent increase in the expression of CD8+CCR4+ T-cells in patients with the mild cardiac form of Chagas disease, compared with patients with the severe cardiac form. In this group of patients, with the severe cardiac form, especially the older patients, it is not uncommon to observe immune response dysfunction and exhaustion, possibly as a result of chronic antigen exposure and myocardial remodeling10. Therefore, the level of some immunological markers, notably memory cells, could be in lower in patients with the severe cardiac form of Chagas disease, supporting the hypothesis that the severity of disease is inversely correlated with the quality of immune responses to T. cruzi11. Thus, with further analysis, this marker may also provide a useful tool for identifying patients who are likely to progress from the mild to a more severe cardiac form of the disease. The expression of other chemokine receptors on the surface of CD8 + T-cells did not vary significantly among the different groups (Figure 2).

FIGURE 2 Ex vivo phenotype expression of chemokine receptors on the surface of CD8+ T-cells of patients with chronic Chagas disease. A: %CD8 CXCR2. B: %CD8 CXCR3. C: %CD8 CXCR4. D: %CD8 CXCR5. E: %CD8 CCR1. F: %CD8 CCR3. G: %CD8 CCR4. H: %CD8 CCR5. IND: indeterminate form (n = 12); CARD1:, mild cardiac form (n = 10); CARD2: severe cardiac form (n = 11). CD8: cluster of differentiation 8; CXCR2, CXCR3, CXCR4, CXCR5, CCR1, CCR3, CCR4, CCR5: chemokine receptors. Median values are indicated by the horizontal lines. The Kruskal-Wallis test was performed, followed by Dunn’s test. Significant differences are indicated by arrows and exact p-values. 

To conclude, our findings suggest that in patients with the cardiac form of chronic Chagas disease, the chemokine receptors CCR3 and CCR4 are involved in the mechanisms of anti-inflammatory and pro-inflammatory immune responses, respectively.

Ethical considerations

The approaches conducted in this study were approved by the Ethics Committee on Research in Human Beings of CPqAM/FIOCRUZ (CAEE: 0032.0.095.000-10) as per the 1975 Declaration of Helsinki, revised in 1983. All subjects provided written informed consent prior to their inclusion in the study.

Acknowledgements

The authors thank the Programa de Desenvolvimento Tecnológico em Insumos para Saúde (PDTIS)/FIOCRUZ for the use of its facilities.

REFERENCES

1. Coura JR, Dias JCP. Epidemiology, control and surveillance of Chagas disease - 100 years after its discovery. Mem Inst Oswaldo Cruz. 2009;104(Suppl 1):31-40. [ Links ]

2. World Health Organization. Chagas Disease (American trypanosomiasis); 2015. http://www.who.int/mediacentre/factsheets/fs340/en/Links ]

3. Cunha-Neto E, Teixeira PC, Nogueira LG, Mady C, Ianni B, Stolf N, et al. Novos conceitos sobre em patogenia da cardiopatia chagásica crônica: perfis de expressão gênica e protéica do miocárdio. Rev Soc Bras Med Trop. 2006;39(Suppl III):59-62. [ Links ]

4. Dutra WO, Menezes CAS, Magalhães LMD, Gollob KJ. Immunoregulatory networks in human Chagas disease. Parasite Immunol. 2014;36(8):377-87. [ Links ]

5. Andrade JP, Marin-Neto JA, Paola AAV, Vilas-Boas F, Oliveira GMM, Bacal F, et al. I Diretriz Latino Americana para o Diagnóstico e Tratamento da Cardiopatia Chagásica. Arq Bras Cardiol. 2011;97(no. 2 supl. 3):1-48. [ Links ]

6. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med. 1971;285(26):1441-6. [ Links ]

7. Gomes JA, Bahia-Oliveira LM, Rocha MO, Busek SC, Teixeira MM, Silva JS, et al. Type 1 chemokine receptor expression in Chagas' disease correlates with morbidity in cardiac patients. Infec Immunity. 2005;73(12):7960-6. [ Links ]

8. Egui A, Thomas MC, Carrilero B, Segovia M, Alonso C, Marañón C, et al. Differential phenotypic and functional profiles of TcCA-2-specific cytotoxic CD8+ T cells in the asymptomatic versus cardiac phase in chagasic patients. PLoS One. 2015;10(3):e0122115. [ Links ]

9. Martin D, Tarleton R. Generation, specificity, and function of CD8+ T cells in Trypanosoma cruzi infection. Immun Rev. 2004;201(1):304-17. [ Links ]

10. Albareda MC, Laucella SA, Alvarez MG, Armenti AH, Bertochi G, Tarleton RL, et al. Trypanosoma cruzi modulates the profile of memory CD8+ T cells in chronic Chagas' disease patients. Int Immunol. 2006;18(3):465-71. [ Links ]

11. Laucella SA, Postan M, Martin D, Hubby Fralish B, Albareda MC, Alvarez MG, et al. Frequency of interferon-gamma-producing T cells specific for Trypanosoma cruzi inversely correlates with disease severity in chronic human Chagas disease. J Infect Dis. 2004;189(5):909-18. [ Links ]

Financial support: This research study received financial support from the Conselho Nacional de Desenvolvimento Científico e Tecnológico [(CNPq) (CNPq/Papes VI/Fiocruz No. 407763/2012-0] and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES). During the study, Y.M. Gomes was research fellow of CNPq (No. 304543/2012-8), A.S. Melo received a CAPES PhD scholarship (064.074.324-21), and M.B. Miranda received a scholarship from CNPq/ Programa Institucional de Bolsas de Iniciação Científica (PIBIC) /Fiocruz.

Received: March 30, 2017; Accepted: June 26, 2017

Corresponding author: Dra. Adriene Siqueira de Melo. e-mail: adrienesmelo@gmail.com

Conflict of interest: The authors declare that there are no conflicts of interest.

Creative Commons License This is an open-access article distributed under the terms of the Creative Commons Attribution License